1. Home
  2. NOAH vs ACRS Comparison

NOAH vs ACRS Comparison

Compare NOAH & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noah Holdings Limited

NOAH

Noah Holdings Limited

N/A

Current Price

$6.16

Market Cap

447.6M

Sector

Finance

ML Signal

N/A

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.46

Market Cap

529.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NOAH
ACRS
Founded
2005
2012
Country
Singapore
United States
Employees
1778
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
447.6M
529.9M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
NOAH
ACRS
Price
$6.16
$3.46
Analyst Decision
Buy
Strong Buy
Analyst Count
4
12
Target Price
★ $10.29
$9.82
AVG Volume (30 Days)
332.1K
★ 2.6M
Earning Date
11-24-2026
11-05-2026
Dividend Yield
★ 10.65%
N/A
EPS Growth
N/A
★ 69.01
EPS
★ N/A
N/A
Revenue
N/A
★ $1,683,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.29
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.24
$2.46
52 Week High
$12.45
$6.60

Technical Indicators

Market Signals
Indicator
NOAH
ACRS
Relative Strength Index (RSI) 30.35 39.18
Support Level N/A $3.24
Resistance Level $8.98 $4.60
Average True Range (ATR) 0.23 0.28
MACD -0.01 -0.02
Stochastic Oscillator 5.85 17.03

Price Performance

Historical Comparison
NOAH
ACRS

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: